Last year’s presidential election invoked a great deal of angst in the pharmaceutical industry, with the cost of drugs taking center stage for a good portion of some candidates’ campaigns. While the things candidates said they would do could very well be different from what they might actually do, their words and records were enough […]
Posts Tagged ‘Biopharmaceutical’